Wanbei Pharma clinches EU GMP for antibiotic API
Shanghai. September 14. INTERFAX-CHINA - Privately held antibiotic producer Anhui Wanbei Pharmaceutical Co. Ltd. (Wanbei Pharma) has won European Union (EU) Good Manufacturing Practice (GMP) certification for lincomycin hydrochloride active pharmaceutical ingredient (API), opening the door for exports to Europe, the firm announced Sept. 13.
Wanbei's production site in Anhui's Suzhou City was inspected by German regulators in March this year, the announcement said.
The antibiotic producer currently holds a 30 percent share of the domestic market for the API, its flagship product, and also exports the ingredient to southeast Asia.
The firm last year won GMP certification for lincomycin hydrochloride in the U.S., becoming the first drug maker in its home province of Anhui to obtain U.S. GMP.
Wanbei also produces antibiotic finished dosages.
-MS